ZURZUVAE is a 14-day treatment that was studied in a
clinical trial comparing it to placebo
ZURZUVAE 50 mg was studied in women with PPD whose symptoms started in the third trimester or within 4 weeks of delivery in a 6-week trial. During the trial, patients took either ZURZUVAE or placebo for 14 days, and were followed up for another 4 weeks. Significantly greater PPD symptom improvement was demonstrated at Day 3, Day 15 (the primary endpoint), and Day 45 compared to placebo, using a standard depression rating scale.
ZURZUVAE is the first and only
FDA-approved oral treatment for
postpartum depression you take
for 14 days
In a clinical study, ZURZUVAE provided a fast way to feel symptom relief
Rapid relief
Women experienced depressive symptom improvement at day 15 and as early as day 3.
Results that lasted
Women continued to feel relief for about 4 weeks after they finished taking ZURZUVAE® (zuranolone).
Talk to your healthcare provider about ZURZUVAE
Download the Conversation Starter
Get help starting the conversation
If you have questions about postpartum depression, ZURZUVAE, or services and resources available to support you, you can call the ZURZUVAE For You support line at 1-844-987-9882.